Mindfulness-Based Program Plus Amygdala and Insula Retraining (MAIR) for the Treatment of Women with Fibromyalgia : a Pilot Randomized Controlled Trial
| Autor: | Virginia Gasión, Mattie Tops, Ariadna Colomer-Carbonell, Xavier Borrás, Juan P. Sanabria-Mazo, Javier García-Campayo, Juan V. Luciano, Jesus Montero-Marin, Héctor Morillo-Sarto, Albert Feliu-Soler, Mayte Navarro-Gil |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Mindfulness mindfulness Fibromyalgia lcsh:Medicine immune-inflammatory markers Immune-inflammatory markers Brain-derived neurotrophic factor law.invention 03 medical and health sciences 0302 clinical medicine Quality of life Randomized controlled trial law medicine Multicomponent intervention 030212 general & internal medicine Amygdala and insula retraining Mind-body techniques Pilot study amygdala and insula retraining business.industry Brief Report lcsh:R brain-derived neurotrophic factor pilot study General Medicine multicomponent intervention medicine.disease mind–body techniques randomized controlled trial Number needed to treat Physical therapy Anxiety Pain catastrophizing fibromyalgia medicine.symptom business Insula 030217 neurology & neurosurgery |
| Zdroj: | Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Journal of Clinical Medicine Journal of Clinical Medicine, Vol 9, Iss 3246, p 3246 (2020) |
| Popis: | The lack of highly effective treatments for fibromyalgia (FM) represents a great challenge for public health. The objective of this parallel, pilot randomized controlled trial (RCT) was two-fold: (1) to analyze the clinical effects of mindfulness plus amygdala and insula retraining (MAIR) compared to a structurally equivalent active control group of relaxation therapy (RT) in the treatment of FM; and (2) to evaluate its impact on immune-inflammatory markers and brain-derived neurotrophic factor (BDNF) in serum. A total of 41 FM patients were randomized into two study arms: MAIR (intervention group) and RT (active control group), both as add-ons of treatment as usual. MAIR demonstrated significantly greater reductions in functional impairment, anxiety, and depression, as well as higher improvements in mindfulness, and self-compassion at post-treatment and follow-up, with moderate to large effect sizes. Significant decreases in pain catastrophizing and psychological inflexibility and improvements in clinical severity and health-related quality of life were found at follow-up, but not at post-treatment, showing large effect sizes. The number needed to treat was three based on the criteria of ≥50% Fibromyalgia Impact Questionnaire (FIQ) reduction post-treatment. Compared to RT, the MAIR showed significant decreases in BDNF. No effect of MAIR was observed in immune-inflammatory biomarkers (i.e., TNF-α, IL-6, IL-10, and hs-CRP). In conclusion, these results suggest that MAIR, as an adjuvant of treatment-as-usual (TAU), appears to be effective for the management of FM symptoms and for reducing BDNF levels in serum. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|